172 related articles for article (PubMed ID: 10380348)
1. Design of protease inhibitors on the basis of substrate stereospecificity.
Kim DH
Biopolymers; 1999; 51(1):3-8. PubMed ID: 10380348
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of papain with 2-benzyl-3,4-epoxybutanoic acid esters. Mechanistic and stereochemical probe for cysteine protease catalysis.
Kim DH; Jin Y; Ryu CH
Bioorg Med Chem; 1997 Nov; 5(11):2103-8. PubMed ID: 9416427
[TBL] [Abstract][Full Text] [Related]
3. N-[2,2-dimethyl-3-(N-(4-cyanobenzoyl)amino)nonanoyl]-L-phenylalanine ethyl ester as a stable ester-type inhibitor of chymotrypsin-like serine proteases: structural requirements for potent inhibition of alpha-chymotrypsin.
Iijima K; Katada J; Yasuda E; Uno I; Hayashi Y
J Med Chem; 1999 Jan; 42(2):312-23. PubMed ID: 9925737
[TBL] [Abstract][Full Text] [Related]
4. From good substrates to good inhibitors: design of inhibitors for serine and thiol proteases.
Baggio R; Shi YQ; Wu YQ; Abeles
Biochemistry; 1996 Mar; 35(11):3351-3. PubMed ID: 8639483
[TBL] [Abstract][Full Text] [Related]
5. Substrate variants versus transition state analogues as noncovalent reversible enzyme inhibitors.
Smyth TP
Bioorg Med Chem; 2004 Aug; 12(15):4081-8. PubMed ID: 15246086
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cysteine proteases by peptides containing aziridine-2,3-dicarboxylic acid building blocks.
Schirmeister T
Biopolymers; 1999; 51(1):87-97. PubMed ID: 10380356
[TBL] [Abstract][Full Text] [Related]
7. Predicted three-dimensional structural models of venom serine protease inhibitors and their interactions with trypsin and chymotrypsin.
Azim MK; Grossmann JG; Zaidi ZH
J Nat Toxins; 1999 Oct; 8(3):363-84. PubMed ID: 10591040
[TBL] [Abstract][Full Text] [Related]
8. Docking studies and model development of tea polyphenol proteasome inhibitors: applications to rational drug design.
Smith DM; Daniel KG; Wang Z; Guida WC; Chan TH; Dou QP
Proteins; 2004 Jan; 54(1):58-70. PubMed ID: 14705024
[TBL] [Abstract][Full Text] [Related]
9. [Enzyme activities of native non-enzymatically glucosylated trypsin, chymotrypsin and papain].
Coradello H; Lubec G; Pollak A; Sternberg M
Padiatr Padol; 1982; 17(2):457-64. PubMed ID: 7099695
[TBL] [Abstract][Full Text] [Related]
10. Structural basis of the unusual stability and substrate specificity of ervatamin C, a plant cysteine protease from Ervatamia coronaria.
Thakurta PG; Biswas S; Chakrabarti C; Sundd M; Jagannadham MV; Dattagupta JK
Biochemistry; 2004 Feb; 43(6):1532-40. PubMed ID: 14769029
[TBL] [Abstract][Full Text] [Related]
11. Stereospecific alkylation of cis-3-chloroacrylic acid dehalogenase by (R)-oxirane-2-carboxylate: analysis and mechanistic implications.
Poelarends GJ; Serrano H; Johnson WH; Whitman CP
Biochemistry; 2004 Jun; 43(22):7187-96. PubMed ID: 15170356
[TBL] [Abstract][Full Text] [Related]
12. Importance of tetrahedral intermediate formation in the catalytic mechanism of the serine proteases chymotrypsin and subtilisin.
Petrillo T; O'Donohoe CA; Howe N; Malthouse JP
Biochemistry; 2012 Aug; 51(31):6164-70. PubMed ID: 22757750
[TBL] [Abstract][Full Text] [Related]
13. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).
Katz BA; Luong C; Ho JD; Somoza JR; Gjerstad E; Tang J; Williams SR; Verner E; Mackman RL; Young WB; Sprengeler PA; Chan H; Mortara K; Janc JW; McGrath ME
J Mol Biol; 2004 Nov; 344(2):527-47. PubMed ID: 15522303
[TBL] [Abstract][Full Text] [Related]
14. Probing the mechanism of hamster arylamine N-acetyltransferase 2 acetylation by active site modification, site-directed mutagenesis, and pre-steady state and steady state kinetic studies.
Wang H; Vath GM; Gleason KJ; Hanna PE; Wagner CR
Biochemistry; 2004 Jun; 43(25):8234-46. PubMed ID: 15209520
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for the substrate specificity of a Bacillus 1,3-1,4-beta-glucanase.
Gaiser OJ; Piotukh K; Ponnuswamy MN; Planas A; Borriss R; Heinemann U
J Mol Biol; 2006 Apr; 357(4):1211-25. PubMed ID: 16483609
[TBL] [Abstract][Full Text] [Related]
16. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
Ellis SW; Hayhurst GP; Lightfoot T; Smith G; Harlow J; Rowland-Yeo K; Larsson C; Mahling J; Lim CK; Wolf CR; Blackburn MG; Lennard MS; Tucker GT
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
[TBL] [Abstract][Full Text] [Related]
17. Peptidyl beta-homo-aspartals (3-amino-4-carboxybutyraldehydes): new specific inhibitors of caspases.
Bajusz S; Fauszt I; Németh K; Barabás E; Juhász A; Patthy M; Bauer PI
Biopolymers; 1999; 51(1):109-18. PubMed ID: 10380358
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of bovine duodenase, a serine protease, with dual trypsin and chymotrypsin-like specificities.
Pletnev VZ; Zamolodchikova TS; Pangborn WA; Duax WL
Proteins; 2000 Oct; 41(1):8-16. PubMed ID: 10944388
[TBL] [Abstract][Full Text] [Related]
19. Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure.
Lang R; Kocourek A; Braun M; Tschesche H; Huber R; Bode W; Maskos K
J Mol Biol; 2001 Sep; 312(4):731-42. PubMed ID: 11575928
[TBL] [Abstract][Full Text] [Related]
20. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
Njoroge FG; Chen KX; Shih NY; Piwinski JJ
Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
